Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMTURNIDE vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension,Edema due to congestive heart failure,Edema due to hepatic cirrhosis,Edema due to nephrotic syndrome,Edema due to corticosteroid or estrogen therapy
Hypertension
10 mg to 20 mg orally once daily, with or without food.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Amiloride is not metabolized and is excreted unchanged in the urine. Hydrochlorothiazide is not extensively metabolized; the majority is excreted unchanged in the urine via renal tubular secretion.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
98% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Vd = 0.15–0.25 L/kg; indicates primarily extracellular distribution.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 40–50% due to first-pass metabolism.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR 15-29 m L/min/1.73 m²: reduce dose to 10 mg once daily. e GFR <15 m L/min/1.73 m² or dialysis: not recommended.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 10 mg once daily. Child-Pugh C: not recommended.
Child-Pugh Class B or C: contraindicated; use not recommended.
Safety and efficacy not established; no recommended dose.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment required, but monitor renal function closely due to age-related decline.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
No FDA boxed warning.
None
Hyperkalemia: Risk is increased in patients with renal impairment, diabetes, or elderly. Monitor serum potassium levels.,Hypersensitivity reactions: May occur with sulfonamide derivatives (hydrochlorothiazide).,Acute angle-closure glaucoma: Has been reported with sulfonamide derivatives.,Electrolyte imbalances: Including hyponatremia, hypochloremia, hypomagnesemia, and hypokalemia.,Renal impairment: Use with caution; may precipitate azotemia.,Hepatic impairment: Use with caution; may precipitate hepatic encephalopathy.,Diabetes: Thiazides may impair glucose tolerance.,Gout: Thiazides may increase serum uric acid levels.,SLE exacerbation: Thiazides may exacerbate systemic lupus erythematosus.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Anuria,Acute or chronic renal insufficiency,Severe renal impairment (e GFR <30 m L/min),Hyperkalemia (serum potassium >5.5 m Eq/L),Hypersensitivity to amiloride, hydrochlorothiazide, or sulfonamide-derived drugs,Concomitant use with potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium (e.g., ACE inhibitors, ARBs)
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Administration with food decreases absorption and may reduce efficacy. Take at least 30 minutes before a meal. No specific food-drug interactions reported.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
FDA Pregnancy Category C. In animal studies, amturnide (finerenone) caused embryofetal toxicity (reduced fetal body weight, delayed ossification, and increased resorptions) at maternal toxic doses. There are no adequate human studies. Risk cannot be ruled out; use only if potential benefit justifies potential risk. First trimester: unknown risk. Second/third trimester: potential for fetal renal effects due to mineralocorticoid receptor blockade.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
No data on presence in human milk. Finerenone and its metabolites are excreted in rat milk. M/P ratio not determined in humans. Due to potential for serious adverse reactions in nursing infants (e.g., hyperkalemia, hypotension), breastfeeding is not recommended during therapy.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dose adjustments established. Pharmacokinetics may be altered due to increased volume of distribution and renal plasma flow; however, no data exist. Use lowest effective dose if essential. Monitor for hyperkalemia and hypotension, which may require dose reduction or discontinuation.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
AMTURNIDE is a first-in-class guanylate cyclase-C receptor agonist for irritable bowel syndrome with constipation (IBS-C). It increases intestinal fluid secretion and transit without significant systemic absorption. Onset of action may occur within 24 hours, but full response may take 2-4 weeks. Avoid in patients with known or suspected mechanical gastrointestinal obstruction. Dose adjustment not required for renal or hepatic impairment.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take once daily on an empty stomach at least 30 minutes before the first meal of the day.,Do not crush or chew the capsule; swallow whole with water.,Common side effects include diarrhea, abdominal pain, and flatulence; diarrhea is most frequent.,Seek medical attention if you experience severe or bloody diarrhea.,Notify your doctor if you are pregnant, breastfeeding, or have a history of bowel obstruction.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMTURNIDE vs ALDORIL D30, answered by our medical review team.
AMTURNIDE is a Antihypertensive Combination that works by AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMTURNIDE and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMTURNIDE is: 10 mg to 20 mg orally once daily, with or without food.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMTURNIDE and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMTURNIDE is classified as Category C. FDA Pregnancy Category C. In animal studies, amturnide (finerenone) caused embryofetal toxicity (reduced fetal body weight, delayed ossification, and increased resorptions) at mate. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.